Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
08/2005
08/10/2005CN1213980C Vitamin D analogues
08/10/2005CN1213752C Treating allergic and inflammatory diseases
08/10/2005CN1213749C Use of obakulactone for preparing medicine for treating hemorrhoid
08/10/2005CN1213733C Method of preparing stable suspension of insoluble microparticles
08/09/2005US6927317 Modulating ramp activity
08/09/2005US6927303 Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same
08/09/2005US6927238 Lipoxin analogs; antiinflammatory activity
08/09/2005US6927234 possessing anti-cancer activity, anti-inflammatory activity, anti-obesity activity, and/or hair growth promotion activity
08/09/2005US6927232 Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles
08/09/2005US6927228 Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation
08/09/2005US6927227 Heterocyclic containing biphenyl aP2 inhibitors and method
08/09/2005US6927224 Anticancer agents; osteoporosis
08/09/2005US6927222 Compounds
08/09/2005US6927221 Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it
08/09/2005US6927220 Bicyclic-substituted 4-amino-pyridopyrimidine derivatives
08/09/2005US6927219 Secondary amides such as N-Adamantan-1-methyl-2-chloro-5-(3,5-dioxo-4,5-dihydro-3H- (1,2,4)triazin-2-yl)-benzamide used as antagonists for biological receptors; antiinflammatiory, anticarcinogenic or antiischemic agents
08/09/2005US6927209 5-thio-β-D-xylopryanoside derivatives, preparation, method, pharmaceutical compositions containing them and their therapeutic use
08/09/2005US6927054 Peptide for use in the diagnosis, prevention, and treatment of inflammation, cancer, arteriosclerosis and degenerative defects
08/09/2005US6926909 Chrono delivery formulations and method of use thereof
08/09/2005US6926898 Albumin fusion proteins
08/09/2005US6926884 GPIb-lipid bond construct and use thereof
08/09/2005CA2327029C Method for making 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline
08/09/2005CA2310627C Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance p antagonists
08/09/2005CA2303217C Use of an angiotensin ii receptor antagonist for the preparation of drugs to increase the survival rate of renal transplant patients
08/09/2005CA2249330C Method of treating heart failure with endothelin antagonists
08/09/2005CA2188164C Benzamide compounds and pharmaceutical use thereof
08/04/2005WO2005070923A1 Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
08/04/2005WO2005070459A1 Method of continuing expression of vector repeatedly administered
08/04/2005WO2005070442A1 A synergistic composition for treating hyperlipidemia
08/04/2005WO2005070413A1 Retinoic acid-containing remedy for diabetes
08/04/2005WO2005069771A2 Small molecule antagonists of bcl-2 family proteins
08/04/2005WO2005034929A3 Tissue remodeling and vascularization
08/04/2005WO2004007457A3 Substituted benzylamine derivatives and methods of use
08/04/2005WO2003000009A3 Stimulation of vascularization with vegf-b
08/04/2005US20050172352 Using presence of allelic mutation in protein kinase c gene as diagnostic indication of heart disease
08/04/2005US20050171354 Heterocyclic amines such as (2S,3S)-3-((1R)-6-methoxy-1-methyl -1-trifluoromethylisochroman-7-yl)methylamino-2-phenyl piperidine, used as analgesics, antiinflammatory agents, or for prophylaxis of cardiovascular disorders
08/04/2005US20050171347 Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
08/04/2005US20050171346 Proteases, kinases enzyme inhibitors; cardiovascular disorders; central nervous system disorders; antiinflammatrory agents; bone disorders; infections
08/04/2005US20050171345 Pteridine compounds for the treatment of psoriasis
08/04/2005US20050171204 2S)-3-(4-{2-[(Cyclohexylmethyl)(heptyl)amino]-2-oxoethoxy}phenyl)-2-ethoxypropanoic acid; treating lipid disorders (dyslipidemias), insulin resistance
08/04/2005US20050171196 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same
08/04/2005US20050171188 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
08/04/2005US20050171187 Making intermediates to alpha-ethyl-2-oxo-1-pyrrolidine acetamide, also referred to as levetiracetam an antihypoxic agent and antiischemic agent; by reduction via catalytic hydrogenation of an alkenyl intermediate
08/04/2005US20050171183 Indole-type inhibitors of p38 kinase
08/04/2005US20050171174 Inhibitors of alpha l beta 2 integrin mediated cell adhesion
08/04/2005US20050171163 MCP-1 receptor antagonists and methods of use thereof
08/04/2005US20050171158 1-(sulfonylaminomethylcarbonyl)-4-cyclohexylpiperidine compounds such as N-[1-(R)-(4-chlorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-methanesulfonamide; various diseases and disorders such as weight control, eating disorders
08/04/2005US20050171154 Carboxylic acid amides
08/04/2005US20050171153 Piperidylcarboxamide derivatives and their use in the treatment of tachykinin-mediated diseases
08/04/2005US20050171151 Administering retinoic acid receptors (RAR) antagonist or an RAR inverse agonist for therapy of hyperlipidemia in mammal
08/04/2005US20050171149 antioxidant properties and peroxisome proliferator activated receptors (PPAR) alpha and PPAR gamma activator properties; cardiovascular diseases, syndrome X, restenosis, diabetes, obesity, hypertension, inflammatory diseases, cancers or neoplasms, neurodegenerative, and skin disorders
08/04/2005US20050171135 1'-[4-[1-(4-fluorophenyl)-1H-indole-3-Y1]-spiro[isobenzofuran-1(3H), 4'-piperidine]hydrohalogenides
08/04/2005US20050171134 such as 4-[4-(1-Amino-1-methylethyl)phenyl]-5-chloro-N-[4-(2-hydroxyethyl)phenyl]pyrimidine-2-amine used as tyrosine kinase inhibitors, for prophylaxis disease states associated with angiogenesis
08/04/2005US20050171129 Polycyclic guanine derivative phosphodiesterase V inhibitors
08/04/2005US20050171125 Novel alkoxypyridine-derivatives
08/04/2005US20050171123 Quinazoline derivatives as medicaments
08/04/2005US20050171122 Mitotic kinesin inhibitors
08/04/2005US20050171113 Product comprising an inhibitor of the transduction of heterotrimeric G protein signals combined with an anti-hypertensive agent for therapeutic use in the treatment of arterial hypertension
08/04/2005US20050171111 E.g., 4-[[5-[[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-6-quinolinyl]hydroxymethyl]-1H-imidazol-1-yl]methyl]-benzonitrile; prevents the membrane attachment of p21ras and blocks the aberrant growth of ras-transformed tumors
08/04/2005US20050171104 Novel thyroid receptor ligands
08/04/2005US20050171102 Semicarbazide derivatives for combating thromboembolic diseases
08/04/2005US20050171101 Neurodegenerative diseases; diseases ascribed by NMDA- and NO-induced neurotoxicity ; ischemia; antiinflammatory; anticancer; antidiabetic; 2-{3-[4-Phenyl-3,6-dihydro-1(2H)-pyridyl]propyl}-6(5H)-phenanthridinone
08/04/2005US20050171100 Dehydrative cyclization of a 3,7-dihydroxy-1,5-diazacyclooctane compounds; one pot process with milder reaction conditions
08/04/2005US20050171098 MCH antagonists and their use in the treatment of obesity
08/04/2005US20050171096 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
08/04/2005US20050171094 Pyrrolopyrimidine derivatives
08/04/2005US20050171092 Chemical compounds
08/04/2005US20050171084 Methods of treatment with lxr modulators
08/04/2005US20050171083 Modified release pharmaceutical formulation
08/04/2005US20050171078 Cholinergic ligands at the nicotinic acetylcholine receptors; diseases related to the cholinergic system; neurodegenerative disorders; pain; antiinflammatory; diagnostic or monitoring tools using labelled forms; 3-Phenyletynyl-quinuclidin-2-ene
08/04/2005US20050171075 Substitued 19-nor-cholestenes; antineoplastic agents, wound healing agents, antiinflammatory agents; autoimmune diseases, transplant rejection inhibition, hyperplasia, graft versus host disease; increased cell growth modulation and differentiation, low calcemic activity
08/04/2005US20050171070 Stable salts of o-acetylsalicylic acid containing basic amino acids II
08/04/2005US20050171068 Novel 4-dedimethylaminotetracycline derivatives
08/04/2005US20050171049 Compounds for the treatment of ischemia
08/04/2005US20050171006 Treatment of congestive heart failure
08/04/2005US20050170348 Nuclear-envelope and nuclear-lamina binding chimeras for modulating gene expression
08/04/2005US20050170344 Chds as modifiers of the p53 pathway and methods of use
08/04/2005US20050169982 Topiramate sodium, topiramate lithium, topiramate potassium, or polymorphs, solvates, hydrates, dehydrates, co-crystals, anhydrous, and amorphous forms; seizures, obesity, neuropathic pain, affective disorders, tobacco cessation, chronic fatigue syndrome, drug addiction; highly soluble, bioavailability
08/04/2005US20050169920 Pecam-1 modulation
08/04/2005US20050169901 controlling cytokine levels by administering extract or secreted products from microorganism; biosynthesis; atheroma, degenerative vascular disease or cardiovascular disease associated with inflammation of the coronary arteries; hypotensive agents, antilipemic agents, anticholesterol agents
08/04/2005US20050169881 O(chloracetyl-carbamoyl) fumagillol -470 conjugated to hydroxypropyl(meth)acrylamide-methacrylic acid copolymer results in a water soluble composition, lowers the neurotoxicity of TNP-470, avoids penetration of TNP-470 to the cerebrospinal fluid
08/04/2005CA2554334A1 Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors
08/04/2005CA2554333A1 Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors
08/04/2005CA2553845A1 A method of modulating pro-inflammatory and inflammatory activity mediated by c-reactive protein
08/04/2005CA2553831A1 Diamino alcohols and their use as renin inhibitors
08/04/2005CA2553714A1 Support accumulating in injured part in vascular channel
08/04/2005CA2552759A1 Combination of organic compounds
08/03/2005EP1559717A2 Oxabispidine compounds useful in the treatment of cardiac arrythmias
08/03/2005EP1559715A1 N-[2-chloro-4-(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-n'-(5-methyl-3-isoxazolyl)urea salt in crystalline form
08/03/2005EP1559710A2 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV, process for their preparation and their use
08/03/2005EP1559428A1 Receptor regulator
08/03/2005EP1559426A1 Percutaneous absorption preparations containing 3-methyl-1-phenyl-2-pyrazolin-5-one
08/03/2005EP1559424A2 The use of inhibitors of the renin-angiotensin system
08/03/2005EP1559422A1 Receptor function controlling agent
08/03/2005EP1559421A1 Blood fluidity improving agent
08/03/2005EP1559374A1 Cyanine dyes
08/03/2005EP1558612A1 Imidazopyridine derivatives, preparation method and pharmaceutical compositions containing same
08/03/2005EP1558598A1 Triazole compounds for the treatment of dysmenorrhoea
08/03/2005EP1558590A1 Alpha-phenyl acetanilide derivatives having an acat inhibiting activity and the therapeutic application thereof
08/03/2005EP1558588A2 Compounds, compositions, and methods
1 ... 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 ... 1595